» Articles » PMID: 17155900

Multiple Biomarker Panels for Early Detection of Ovarian Cancer

Overview
Journal Future Oncol
Specialty Oncology
Date 2006 Dec 13
PMID 17155900
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Ovarian cancer is the eighth most common cause of cancer mortality in women. It is diagnosed in more than 20,000 women in the USA each year and approximately 15,000 women die of the disease annually. The majority of patients are diagnosed with advanced-stage ovarian cancer, as this deadly disease causes minimal and nonspecific symptoms until late in the course of the disease. No standardized screening test exists to reliably detect ovarian cancer. Cancer antigen (CA)-125 is a protein antigen found at abnormally high levels in the blood of many women with ovarian cancer. Most healthy women have CA-125 levels of below 35 units/microl of blood serum. However, a number of noncancerous conditions can cause elevated CA 125 levels, and many women with early-stage ovarian cancer have normal CA-125 levels. Owing to these limitations, this test is not recommended for routine screening in women who are not at high risk or who do not have specific symptoms of the disease. Currently, many researchers are focusing on simultaneous examination of multiple markers to increase sensitivity of the screening test for early detection of ovarian cancer. Analysis of the current literature shows that combining several biomarkers dramatically improves sensitivity of CA-125 in ovarian cancer patients. This article provides a comprehensive overview of existing studies in the area of multimarker panel development for the early detection and monitoring of ovarian cancer. Our literature review demonstrates that a multimarker approach for the generation of a prototype assay for early detection of ovarian cancer has a great potential to lead to the development of a screening test for this disease.

Citing Articles

Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling.

Dhar C, Ramachandran P, Xu G, Pickering C, Caval T, Wong M Br J Cancer. 2024; 130(10):1716-1724.

PMID: 38658783 PMC: 11091186. DOI: 10.1038/s41416-024-02644-4.


Lineage specific extracellular vesicle-associated protein biomarkers for the early detection of high grade serous ovarian cancer.

Trinidad C, Pathak H, Cheng S, Tzeng S, Madan R, Sardiu M Sci Rep. 2023; 13(1):18341.

PMID: 37884576 PMC: 10603107. DOI: 10.1038/s41598-023-44050-5.


A panel of seven protein tumour markers for effective and affordable multi-cancer early detection by artificial intelligence: a large-scale and multicentre case-control study.

Luan Y, Zhong G, Li S, Wu W, Liu X, Zhu D EClinicalMedicine. 2023; 61:102041.

PMID: 37387788 PMC: 10300313. DOI: 10.1016/j.eclinm.2023.102041.


The diagnostic and prognostic potential of the EGFR/MUC4/MMP9 axis in glioma patients.

Quesnel A, Coles N, Polvikoski T, Karagiannis G, Angione C, Islam M Sci Rep. 2022; 12(1):19868.

PMID: 36400876 PMC: 9674618. DOI: 10.1038/s41598-022-24099-4.


Advancing microfluidic diagnostic chips into clinical use: a review of current challenges and opportunities.

Iyer V, Yang Z, Ko J, Weissleder R, Issadore D Lab Chip. 2022; 22(17):3110-3121.

PMID: 35674283 PMC: 9798730. DOI: 10.1039/d2lc00024e.